{"id":"NCT02344290","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults","officialTitle":"Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-26","primaryCompletion":"2023-08-21","completion":"2023-08-21","firstPosted":"2015-01-22","resultsPosted":"2024-10-15","lastUpdate":"2025-09-04"},"enrollment":7769,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["HIV","Cardiovascular Diseases"],"interventions":[{"type":"DRUG","name":"Pitavastatin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pitavastatin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"People with HIV are at risk for cardiovascular disease (CVD). This study evaluated the use of pitavastatin to reduce the risk of CVD in adults with HIV on antiretroviral therapy (ART).\n\nThe REPRIEVE trial consisted of two parallel identical protocols:\n\n* REPRIEVE (A5332) was funded by the NHLBI, with additional infrastructure support provided by the NIAID, and was conducted in U.S and select international sites (approximately 120 sites in 11 countries).\n* REPRIEVE (EU5332) was co-sponsored by NEAT ID and MGH, and was conducted at 13 sites in Spain.","primaryOutcome":{"measure":"Incidence Rate of Major Adverse Cardiovascular Event (MACE)","timeFrame":"From entry through end of study. Follow-up time varied depending on time of enrollment (the median follow-up time was 5.6 years).","effectByArm":[{"arm":"Pitavastatin","deltaMin":4.95,"sd":null},{"arm":"Placebo","deltaMin":7.77,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":137,"countries":["United States","Botswana","Brazil","Canada","Haiti","India","Peru","Puerto Rico","South Africa","Spain","Thailand","Uganda","Zimbabwe"]},"refs":{"pmids":["24239921","28277924","30928825","30928823","32645161","32160827","32645164","32645162","32645160","32645159","32645158","34134131","34185068","34888395","34794178","35147583","35165682","35235653","35413022","35876637","35535576","36101518","35975297","36525544","36462699","36805331","36825498","36998633","36966617","37439633","37486775","37503623","37869406","38197863","38381407","38533953","38692296","40924496","40576558","40482662","40373520","40207047","40180472","39832519","39661372","39435321","39374532","39253712","39159048","38180893","37368931","32645163"],"seeAlso":["http://reprievetrial.org/","https://rsc.niaid.nih.gov/sites/default/files/daids-ae-grading-table-v2-nov2014.pdf","https://database.ich.org/sites/default/files/E2A_Guideline.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":750,"n":3888},"commonTop":["Diabetes mellitus (incl subtypes)","Renal function analyses","Physical examination procedures and organ system status","Muscle pains","General nutritional disorders NEC"]}}